GlassScriptPhysician profile
Bernard Pare
NPI 1881673093
$22,325.33
in general payments reported to CMS, 2019-2025
57 companies · $2,820 in 2025
The $2,820 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,230 · 2020: $2,727 · 2021: $3,398 · 2022: $3,553 · 2023: $3,310 · 2024: $3,287 · 2025: $2,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,416.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,525.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,785.90 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,211.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,565.26 | 2019-2025 | |
| Lilly USA, LLC | $1,522.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,368.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $1,063.85 | 2019-2025 | |
| Astellas Pharma US INC | $860.82 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.88 | 2019-2024 | Jardiance, Tradjenta, Ofev |
| Amarin Pharma, INC. | $768.64 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $621.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $411.25 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $389.58 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $377.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $327.64 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Pare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.